<DOC>
	<DOC>NCT00832117</DOC>
	<brief_summary>The purpose of this study is to determine the highest dose of ixabepilone that can be given safely with cisplatin without causing severe or life-threatening side effects and for some patients with non-small cell lung cancer, the effects (good or bad) on your cancer will also be studied</brief_summary>
	<brief_title>Phase I Combination Ixabepilone + Cisplatin</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Escalation Phase Subjects: Primary solid tumor not curable by local measures such as surgery, radiation Men and women age ≥ 18 Exclusion: More than 2 prior chemotherapy containing regimens for metastatic disease No prior exposure to cisplatin or ixabepilone Expansion Phase Subjects: Advanced Nonsmall cell lung cancer Men and women age ≥ 18 Exclusion: No prior chemotherapycontaining regimen for metastatic disease No prior exposure to cisplatin or ixabepilone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Lung Cancer (NSCLC)</keyword>
</DOC>